The Journal of Heart and Lung Transplantation
Volume 27, Issue 12 , Pages 1293-1301 , December 2008

Value of FOXP3 Expression in Peripheral Blood as Rejection Marker After Miniature Swine Lung Transplantation

Presented at the American Transplant Congress (ATC), May 2007, San Francisco, California, and at the 28th annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), April 2008, Boston, Massachusetts where Naoki Satoda was a nominee for the Philip K. Caves Award.

  • Naoki Satoda, MD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Tsuyoshi Shoji, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Yanling Wu, MD, PhD

      Affiliations

    • Innovation Center for Immunoregulation Technologies and Drugs, Transplant Tolerance Unit, Kyoto University, Kyoto, Japan
    • ,
  • Takuji Fujinaga

      Affiliations

    • Department of Organ Preservation Technology, Kyoto University, Kyoto, Japan
    • ,
  • Fengshi Chen, MD, PhD

      Affiliations

    • Department of Organ Preservation Technology, Kyoto University, Kyoto, Japan
    • ,
  • Akihiro Aoyama, MD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Ji Tian Zhang, MD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Ayuko Takahashi, MD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Toshihiro Okamoto, MD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Izumi Matsumoto

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Hiroaki Sakai, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Ying Li, MD, PhD

      Affiliations

    • Innovation Center for Immunoregulation Technologies and Drugs, Transplant Tolerance Unit, Kyoto University, Kyoto, Japan
    • ,
  • Xiangdong Zhao, MD, PhD

      Affiliations

    • Department of Organ Preservation Technology, Kyoto University, Kyoto, Japan
    • ,
  • Toshiaki Manabe, MD, PhD

      Affiliations

    • Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan
    • ,
  • Eiji Kobayashi, MD, PhD

      Affiliations

    • Organ Replacement Research Center, Jichi Medical School, Shimono, Japan
    • ,
  • Shimon Sakaguchi, MD, PhD

      Affiliations

    • Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
    • ,
  • Hiromi Wada, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Hidenori Ohe, MD
    • ,
  • Shinji Uemoto, MD, PhD

      Affiliations

    • Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • ,
  • Junichi Tottori

      Affiliations

    • Japan Farm CLAWN Institute, Isa, Kagoshima, Japan
    • ,
  • Toru Bando, MD, PhD

      Affiliations

    • Department of Organ Preservation Technology, Kyoto University, Kyoto, Japan
    • ,
  • Hiroshi Date, MD, PhD

      Affiliations

    • Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    • ,
  • Takaaki Koshiba, MD, PhD

      Affiliations

    • Innovation Center for Immunoregulation Technologies and Drugs, Transplant Tolerance Unit, Kyoto University, Kyoto, Japan
    • Corresponding Author InformationReprint requests: Takaaki Koshiba, MD, PhD, Innovation Center for Immunoregulation Technologies and Drugs, Transplant Tolerance Unit, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Telephone: 81-75-751-4328. Fax: 81-75-751-4328

Received 13 April 2008 ,Revised 1 August 2008 ,Accepted 21 August 2008.

References 

  1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–590
  2. Pomfret EA, Fryer JP, Sima CS, Lake JR, Merion RM. Liver and intestine transplantation in the United States, 1996–2005. Am J Transplant. 2007;7:1376–1389
  3. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996–2005. Am J Transplant. 2007;7:1359–1375
  4. Garrity ER, Moore J, Mulligan MS, Shearon TH, Zucker MJ, Murray S. Heart and lung transplantation in the United States, 1996–2005. Am J Transplant. 2007;7:1390–1403
  5. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart–lung transplantation report—2007. J Heart Lung Transplant. 2007;26:782–795
  6. Prop J, Kuijpers K, Petersen AH, Bartels HL, Nieuwenhuis P, Wildevuur CR. Why are lung allografts more vigorously rejected than hearts?. J Heart Transplant. 1985;4:433–436
  7. Burke CM, Glanville AR, Theodore J, Robin ED. Lung immunogenicity, rejection, and obliterative bronchiolitis. Chest. 1987;92:547–549
  8. Tikkanen J, Lemstrom K, Halme M, Pakkala S, Taskinen E, Koskinen P. Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart–lung allograft recipients. Clin Transplant. 2001;15:77–88
  9. Trulock EP. Management of lung transplant rejection. Chest. 1993;103:1566–1576
  10. Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet. 2004;363:1503–1508
  11. Yousem SA. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol. 1996;27:269–273
  12. De Hoyos A, Chamberlain D, Schvartzman R, et al. Prospective assessment of a standardized pathologic grading system for acute rejection in lung transplantation. Chest. 1993;103:1813–1818
  13. Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of lung transplant rejection by hepatocyte growth factor. Lancet. 2004;363:1503–1508
  14. Hodge SJ, Hodge GL, Reynolds PN, Holmes MD. Differential rates of apoptosis in bronchoalveolar lavage and blood of lung transplant patients. J Heart Lung Transplant. 2005;24:1305–1314
  15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061
  16. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004;6:745–751
  17. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–336
  18. Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201:1037–1044
  19. Heslan JM, Beriou G, Le Luduec JB, et al. Accumulation of T cells with potent regulatory properties and restricted Vbeta7-TCR rearrangements in tolerated allografts. Transplantation. 2005;80:1476–1484
  20. Kitazawa Y, Fujino M, Sakai T, et al. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant. 2008;27:362–371
  21. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005;80:110–117
  22. Dijke IE, Velthuis JH, Caliskan K, et al. Intragraft FOXP3 mRNA expression reflects antidonor immune reactivity in cardiac allograft patients. Transplantation. 2007;83:1477–1484
  23. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353:2342–2351
  24. Veronese F, Rotman S, Smith RN, Benedict Cosimi A, Colvin RB. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant. 2007;7:914–922
  25. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 2004;4:2118–2125
  26. Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol. 2004;16:1189–1201
  27. Koshiba T, Kitade H, Van Damme B, et al. Regulatory cell-mediated tolerance does not protect against chronic rejection. Transplantation. 2003;76:588–596
  28. Shoji T, Wain JC, Houser SL, et al. Indirect recognition of MHC class I allopeptides accelerates lung allograft rejection in miniature swine. Am J Transplant. 2005;5:1626–1634
  29. Allan JS, Wain JC, Schwarze ML, et al. Modeling chronic lung allograft rejection in miniature swine. Transplantation. 2002;73:447–453
  30. Omasa M, Hasegawa S, Bando T, et al. Application of ET-Kyoto solution in clinical lung transplantation. Ann Thorac Surg. 2004;77:338–339
  31. Koletsis E, Chatzimichalis A, Apostolakis E, et al. In situ cooling in a lung hilar clamping model of ischemia–reperfusion injury. Exp Biol Med (Maywood). 2006;231:1410–1420
  32. Overbergh L, Gysemans C, Mathieu C. Quantification of chemokines by real-time reverse transcriptase PCR: applications in type 1 diabetes. Expert Rev Mol Diagn. 2006;6:51–64
  33. Dijke IE, Caliskan K, Korevaar SS, et al. FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transplant Immunol. 2008;18:250–254
  34. Stenard F, Nguyen C, Cox K, et al. Decreases in circulating CD4 (+) CD25 (hi) FOXP3 (+) cells and increases in intragraft FOXP3 (+) cells accompany allograft rejection in pediatric liver allograft recipients. Pediatr Transplant. 2008;(in press).
  35. Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006;82:550–557
  36. de Groot-Kruseman HA, Baan CC, Hagman EM, et al. Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation. Heart. 2002;87:363–367
  37. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004;172:6519–6523
  38. Antony PA, Paulos CM, Ahmadzadeh M, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006;176:5255–5266
  39. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37:129–138
  40. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol. 2007;123:18–29
  41. Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients (An analysis of 200 consecutive procedures). Chest. 1992;102:1049–1054
  42. Date H, Aoe M, Nagahiro I, et al. Living-donor lobar lung transplantation for various lung diseases. J Thorac Cardiovasc Surg. 2003;126:476–481
  43. Colombat M, Groussard O, Lautrette A, et al. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection (Clinicopathologic correlations during the first 6 months after lung transplantation). Hum Pathol. 2005;36:387–394
  44. Simon T, Opelz G, Wiesel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant. 2003;3:1121–1127
  45. Sharma VK, Bologa RM, Li B, et al. Molecular executors of cell death—differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation. 1996;62:1860–1866
  46. Yannaraki M, Rebibou JM, Ducloux D, et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transplant Int. 2006;19:759–768
  47. Kanmaz T, Feng P, Torrealba J, et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation. 2004;78:1002–1007

 Supported by grants-in-aids from the Ministry of Health, Labor and Welfare; Astellas Pharma, Inc.; and Otsuka Pharmaceutical.

PII: S1053-2498(08)00615-3

doi: 10.1016/j.healun.2008.08.006

The Journal of Heart and Lung Transplantation
Volume 27, Issue 12 , Pages 1293-1301 , December 2008

Article Tools

* Image Usage & Resolution